Stocks Health care CRMD
NASDAQ · Health careCorMedix Inc. (CRMD)
CorMedix Inc. brought in $462.2M of revenue over the twelve months to June 30, 2026. Net income was $187.2M, a net margin of 40.5%. Operating cash flow minus capital spending left $172.8M of free cash flow in fiscal 2025. At June 30, 2026 it held $256.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What CorMedix Inc. does
CorMedix Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CRMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $311.7M | $163.1M | $2.04 | $172.8M |
| 2024 | $43.5M | -$17.9M | -$0.30 | -$50.7M |
| 2023 | n/a | -$46.3M | -$0.91 | -$38.7M |
| 2022 | $65.4K | -$29.7M | -$0.74 | -$24.6M |
| 2021 | $190.9K | -$28.2M | -$0.75 | -$22.6M |
| 2020 | $239.2K | -$22M | -$0.77 | -$22.1M |
Where CRMD ranks in Health care
Latest SEC filings
What CorMedix Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- August 7, 2026Other event 8-K
- July 2, 2026Other event 8-K
- July 1, 2026Auditor change 8-K
- June 25, 2026Form S-8 POS filing S-8 POS
- June 24, 2026
- June 12, 2026Passive stake changed SCHEDULE 13G/A
- June 12, 2026Passive stake changed SCHEDULE 13G/A
- June 8, 2026
What is CRMD worth? A DCF from its reported cash flow
Insider trades
What the people running CorMedix Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 4 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 18, 2026 | Dillione JanetDirector | Exercised options | 48,909 | - |
| August 29, 2026 | Zelnick Kaufman BethChief Legal Officer | Shares withheld for tax | 8,424 | $69.9K |
| August 29, 2026 | Hurlburt ElizabethChief Operating Officer | Shares withheld for tax | 8,076 | $67K |
| August 29, 2026 | Blum SusanChief Financial Officer | Shares withheld for tax | 8,424 | $69.9K |
Questions about CRMD
What does CorMedix Inc. do?
CorMedix Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CRMD.
Is CorMedix Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $187.2M on revenue of $462.2M, a net margin of 40.5%.
How much revenue does CorMedix Inc. make?
Over the twelve months to June 30, 2026 CorMedix Inc. reported revenue of $462.2M.
When did CorMedix Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 18, 2026.
Similar companies
Compare CRMD with
Follow CRMD
Get an email when CorMedix Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CRMD: get an email when it filesWhere the numbers come from
Financial figures are the values CorMedix Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.